Westminster Health Forum policy conference
The future for UK regulation of medicines, medical devices and clinical trials – transparency and public trust, safety and enforcement, and support for innovation
Timing: Morning, Thursday, 16th July 2020
*****Taking Place Online*****

Draft agenda subject to change

WESTMINSTER HEALTH FORUM

8.30 Registration

9.00 **Chair's opening remarks**
Daniel Zeichner MP

9.05 **Priorities for regulation and the role of the MHRA**
Jonathan Mogford, Policy Director, MHRA
Questions and comments from the floor

9.35 Break

9.40 **Meeting the challenge of regulating and developing medicines during the Covid-19 Pandemic**
Dr Aldo Faisal, Reader in Neurotechnology, Department of Bioengineering and Department of Computing, Imperial College London and Director, UKRI Centre in AI for Healthcare, Imperial College London

9.50 **'Transforming care: industry view on seizing opportunities to support access to innovation'**
Hilary Hutton-Squire, General Manager, UK and Ireland, Gilead Sciences

10.00 Questions and comments from the floor

Stakeholder priorities for medicine regulation - safety, research integrity and innovation

10.15 *Developing a regulatory ecosystem that supports innovation, provides regulatory certainty, and is transparent*
Erin Brooks, Head of Regulatory, Roche

10.25 *'Research transparency, public involvement and proportionality'*
Juliet Tizzard, Director of Policy, Health Research Authority

10.35 *Key issues for patient care - research, communication and access to treatment*
Neil Bennett, Director of Research, Action Duchenne

10.45 *Developing methods and technologies to ensure safe and effective medicines*
Dr Jan Turner, Director, Safer Medicines Trust

10.55 *Prioritising support for the uptake and adoption of innovations*
Patrick Stephenson, Director of Innovation and Healthcare, Fujitsu

11.05 Questions and comments from the floor

11.30 **Chairs closing remarks**
Daniel Zeichner MP

11.35 Break

11.40 **Chair's opening remarks**
Anne Marie Morris MP

11.55 **The future for collaboration with the EU, and the UK's relationship with the EMA**
Sarah Faircliffe, Legal Director, Bird & Bird

12.05 **'Using technology to tackle irresponsible medical ads - partnership with online platforms and statutory enforcement partners'**
Jane Eldridge, Head of Casework, Advertising Standards Authority

12.15 **Key issues for ensuring quality in clinical trials and the medicine approval process - research integrity, public trust and workforce development**
Eugene Pozniak, Managing Director, Siyemi Learning and Programme Director, European CME Forum
Phil Brown, Director of Technical and Regulatory, Association of British HealthTech Industries
Professor Pamela Kearns, Director, Institute of Cancer and Genomic Sciences and Director, Cancer Research UK Clinical Trials Unit, University of Birmingham
Questions and comments from the floor with **Sarah Faircliffe**, Legal Director, Blue & Bird and **Jane Eldridge**, Head of Casework, Advertising Standards Authority

12.55 **Chair's and Westminster Health Forum closing remarks**
Anne Marie Morris MP
Michael Ryan, Deputy Editor, Westminster Health Forum